Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction

Virology

Volumn 423, Issue 1, 2012, Pages 97-106

  Huang, Xin ^a,b   Jin, Wei ^a,b   Hu, Kai ^a,b   Luo, Sukun ^a,b   Du, Tao ^a,b   Griffin, George E ^c   Shattock, Robin J ^c   Hu, Qinxue ^a,c  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Deglycosylation; Envelope glycoprotein; HIV 1; Immune response; Immunization; Infectivity; Neutralizing activity

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; FEMALE; GLYCOSYLATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; SENSITIVITY ANALYSIS; VIRUS INFECTION; VIRUS NEUTRALIZATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; CONSERVED SEQUENCE; FEMALE; GLYCOSYLATION; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES; PROTEIN BINDING;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84855343161     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.11.023     Document Type: Article

References (72)

1. Aihara H., Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat. Biotechnol. 1998, 16(9):867-870.
2. Arias M.A., Loxley A., Eatmon C., Van Roey G., Fairhurst D., Mitchnick M., Dash P., Cole T., Wegmann F., Sattentau Q., Shattock R. Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen. Vaccine 2011, 29(6):1258-1269.
3. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat. Rev. Microbiol. 2007, 5(8):583-597.
4. Balzarini J., Van Laethem K., Peumans W.J., Van Damme E.J., Bolmstedt A., Gago F., Schols D. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J. Virol. 2006, 80(17):8411-8421.
5. Beddows S., Franti M., Dey A.K., Kirschner M., Iyer S.P., Fisch D.C., Ketas T., Yuste E., Desrosiers R.C., Klasse P.J., Maddon P.J., Olson W.C., Moore J.P. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007, 360(2):329-340.
6. Berman P.W., Gregory T.J., Riddle L., Nakamura G.R., Champe M.A., Porter J.P., Wurm F.M., Hershberg R.D., Cobb E.K., Eichberg J.W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345(6276):622-625.
7. Bolmstedt A., Sjolander S., Hansen J.E., Akerblom L., Hemming A., Hu S.L., Morein B., Olofsson S. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 12(3):213-220.
8. Bures R., Gaitan A., Zhu T., Graziosi C., McGrath K.M., Tartaglia J., Caudrelier P., El Habib R., Klein M., Lazzarin A., Stablein D.M., Deers M., Corey L., Greenberg M.L., Schwartz D.H., Montefiori D.C. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2000, 16(18):2019-2035.
9. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., Kelly J.W., Rudd P.M., Dwek R.A., Katinger H., Burton D.R., Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300(5628):2065-2071.
10. Cole K.S., Steckbeck J.D., Rowles J.L., Desrosiers R.C., Montelaro R.C. Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3. J. Virol. 2004, 78(3):1525-1539.
11. Connor R.I., Korber B.T., Graham B.S., Hahn B.H., Ho D.D., Walker B.D., Neumann A.U., Vermund S.H., Mestecky J., Jackson S., Fenamore E., Cao Y., Gao F., Kalams S., Kunstman K.J., McDonald D., McWilliams N., Trkola A., Moore J.P., Wolinsky S.M. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 1998, 72(2):1552-1576.
12. Cooney E.L., McElrath M.J., Corey L., Hu S.L., Collier A.C., Arditti D., Hoffman M., Coombs R.W., Smith G.E., Greenberg P.D. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(5):1882-1886.
13. Davenport T.M., Friend D., Ellingson K., Xu H., Caldwell Z., Sellhorn G., Kraft Z., Strong R.K., Stamatatos L. Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. J. Virol. 2011, 85(14):7095-7107.
14. Devito C., Zuber B., Schroder U., Benthin R., Okuda K., Broliden K., Wahren B., Hinkula J. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J. Immunol. 2004, 173(11):7078-7089.
15. Dey B., Pancera M., Svehla K., Shu Y., Xiang S.H., Vainshtein J., Li Y., Sodroski J., Kwong P.D., Mascola J.R., Wyatt R. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 2007, 81(11):5579-5593.
16. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 2010, 84(20):10510-10521.
17. Duenas-Decamp M.J., Peters P., Burton D., Clapham P.R. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 2008, 82(12):5807-5814.
18. Dumonceaux J., Goujon C., Joliot V., Briand P., Hazan U. Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120. J. Virol. 2001, 75(11):5425-5428.
19. Dunfee R.L., Thomas E.R., Wang J., Kunstman K., Wolinsky S.M., Gabuzda D. Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology 2007, 367(1):222-234.
20. Earl P.L., Sugiura W., Montefiori D.C., Broder C.C., Lee S.A., Wild C., Lifson J., Moss B. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J. Virol. 2001, 75(2):645-653.
21. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005, 191(5):654-665.
22. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., DeVico A., Pal R. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(18):11842-11847.
23. Gallaher W.R., Ball J.M., Garry R.F., Martin-Amedee A.M., Montelaro R.C. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses 1995, 11(2):191-202.
24. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., Heyward W.L., Jobes D.V., Popovic V., Self S.G., Sinangil F., Burke D., Berman P.W. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 2005, 191(5):666-677.
25. Graham B.S., Wright P.F. Candidate AIDS vaccines. N. Engl. J. Med. 1995, 333(20):1331-1339.
26. Gray E.S., Moore P.L., Pantophlet R.A., Morris L. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization. J. Virol. 2007, 81(19):10769-10776.
27. Hanson C.V. Measuring vaccine-induced HIV neutralization: report of a workshop. AIDS Res. Hum. Retroviruses 1994, 10(6):645-648.
28. Hu Q., Trent J.O., Tomaras G.D., Wang Z., Murray J.L., Conolly S.M., Navenot J.M., Barry A.P., Greenberg M.L., Peiper S.C. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 2000, 302(2):359-375.
29. Hu Q.X., Barry A.P., Wang Z.X., Connolly S.M., Peiper S.C., Greenberg M.L. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 2000, 74(24):11858-11872.
30. Hu Q., Napier K.B., Trent J.O., Wang Z., Taylor S., Griffin G.E., Peiper S.C., Shattock R.J. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. J. Mol. Biol. 2005, 350(4):699-712.
31. Hu Q., Mahmood N., Shattock R.J. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 2007, 368(1):145-154.
32. Hu Q., Huang X., Shattock R.J. CCR5 utilization of transmitted and early founder HIV-1 envelopes and the sensitivity to small-molecule CCR5 inhibitors. J. Gen. Virol. 2010, 91:2965-2973.
33. Huang X., Jin W., Griffin G.E., Shattock R.J., Hu Q. Removal of two high-mannose N-linked glycans on gp120 renders human immunodeficiency virus 1 largely resistant to the carbohydrate-binding agent griffithsin. J. Gen. Virol. 2011, 92(Pt 10):2367-2373.
34. Jeffs S.A., Goriup S., Kebble B., Crane D., Bolgiano B., Sattentau Q., Jones S., Holmes H. Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004, 22(8):1032-1046.
35. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(21):7552-7557.
36. Kim M., Qiao Z.S., Montefiori D.C., Haynes B.F., Reinherz E.L., Liao H.X. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res. Hum. Retroviruses 2005, 21(1):58-67.
37. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003, 313(2):387-400.
38. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 2001, 75(7):3435-3443.
39. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393(6686):648-659.
40. Lee W.R., Syu W.J., Du B., Matsuda M., Tan S., Wolf A., Essex M., Lee T.H. Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(6):2213-2217.
41. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 1990, 265(18):10373-10382.
42. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., Montefiori D., Polacino P., Hu S.L. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 2008, 82(2):638-651.
43. Ly A., Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J. Virol. 2000, 74(15):6769-6776.
44. Malenbaum S.E., Yang D., Cavacini L., Posner M., Robinson J., Cheng-Mayer C. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J. Virol. 2000, 74(23):11008-11016.
45. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 1996, 173(2):340-348.
46. Matthews T.J. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retroviruses 1994, 10(6):631-632.
47. McCaffrey R.A., Saunders C., Hensel M., Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J. Virol. 2004, 78(7):3279-3295.
48. Montefiori D.C. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol. Biol. 2009, 485:395-405.
49. Mori K., Sugimoto C., Ohgimoto S., Nakayama E.E., Shioda T., Kusagawa S., Takebe Y., Kano M., Matano T., Yuasa T., Kitaguchi D., Miyazawa M., Takahashi Y., Yasunami M., Kimura A., Yamamoto N., Suzuki Y., Nagai Y. Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model. J. Virol. 2005, 79(16):10386-10396.
50. Morner A., Douagi I., Forsell M.N., Sundling C., Dosenovic P., O'Dell S., Dey B., Kwong P.D., Voss G., Thorstensson R., Mascola J.R., Wyatt R.T., Karlsson Hedestam G.B. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 2009, 83(2):540-551.
51. Ogert R.A., Lee M.K., Ross W., Buckler-White A., Martin M.A., Cho M.W. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 2001, 75(13):5998-6006.
52. Pantophlet R., Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 2006, 24:739-769.
53. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F., Hu D., Tappero J.W., Choopanya K. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194(12):1661-1671.
54. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 2001, 276(16):13433-13441.
55. Polzer S., Dittmar M.T., Schmitz H., Meyer B., Muller H., Krausslich H.G., Schreiber M. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1. Glycobiology 2001, 11(1):11-19.
56. Polzer S., Dittmar M.T., Schmitz H., Schreiber M. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 2002, 304(1):70-80.
57. Quinones-Kochs M.I., Buonocore L., Rose J.K. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J. Virol. 2002, 76(9):4199-4211.
58. Radaelli A., Bonduelle O., Beggio P., Mahe B., Pozzi E., Elli V., Paganini M., Zanotto C., De Giuli Morghen C., Combadiere B. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. Vaccine 2007, 25(11):2128-2138.
59. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 1998, 4(6):679-684.
60. Robinson H.L. Working towards an HIV/AIDS vaccine. Hum. Vaccin. 2009, 5(7):436-438.
61. Sagar M., Wu X., Lee S., Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 2006, 80(19):9586-9598.
62. Sanders R.W., Venturi M., Schiffner L., Kalyanaraman R., Katinger H., Lloyd K.O., Kwong P.D., Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002, 76(14):7293-7305.
63. Sanders R.W., van Anken E., Nabatov A.A., Liscaljet I.M., Bontjer I., Eggink D., Melchers M., Busser E., Dankers M.M., Groot F., Braakman I., Berkhout B., Paxton W.A. The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology 2008, 5:10.
64. Scanlan C.N., Pantophlet R., Wormald M.R., Ollmann Saphire E., Stanfield R., Wilson I.A., Katinger H., Dwek R.A., Rudd P.M., Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1->2 mannose residues on the outer face of gp120. J. Virol. 2002, 76(14):7306-7321.
65. Schultz A.M., Bradac J.A. The HIV vaccine pipeline, from preclinical to phase III. AIDS 2001, 15(Suppl 5):S147-S158.
66. Swanson C.M., Malim M.H. SnapShot: HIV-1 proteins. Cell 2008, 133(4):742. (742 e1).
67. Vaine M., Wang S., Hackett A., Arthos J., Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28(17):2999-3007.
68. Veazey R.S., Klasse P.J., Schader S.M., Hu Q., Ketas T.J., Lu M., Marx P.A., Dufour J., Colonno R.J., Shattock R.J., Springer M.S., Moore J.P. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005, 438(7064):99-102.
69. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326(5950):285-289.
70. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
71. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280(5371):1884-1888.
72. Zhu X., Borchers C., Bienstock R.J., Tomer K.B. Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 2000, 39(37):11194-11204.